Burlington Coat Factory breaks own fundraising record for the LLS

Now celebrating its tenth year as a major fundraising partner of the Leukemia & Lymphoma Society, Burlington Coat Factory broke its own previous record for money raised in a year for the LLS in 2011 by raising over $3 million. In the 10-year partnership, Burlington Coat Factory has raised over $13 million for the major blood cancer charity.

This year, Burlington Coat Factory raised the incredible amount by way of two programs:

-- A company-wide initiative involving all 462 store locations nationwide, in which its customers purchased paper balloon icons to support the LLS;
-- The participation by Burlington's employees in 120 "Light The Night Walk" teams in 78 different cities across the United States.

"Volunteerism and community giving have long been part of the Burlington Coat Factory legacy, and we are delighted to have such a significant and rich history with The Leukemia & Lymphoma Society," said Thomas Kingsbury, Burlington president and CEO. "From in-store sales of our iconic paper balloons to nationwide employee participation, we are honored to have made such a profound impact on those affected by blood cancers."

Links:
The Leukemia & Lymphoma Society
Burlington Coat Factory

Source: PR Newswire

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap